Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy.
Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research.
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Opinion: Sex inclusion in basic research drives discovery.
Pervasive Axonal Transport Deficits in Multiple Sclerosis Models.
Effect of IFN β-1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis.
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome.
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE).
FDA approval announcement for ofatumumab
Receptos doses first patient in Phase 2 trial for RPC1063 in ulcerative colitis
Phase III study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis (TOPIC)
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.
Safety Study of Interferon Beta-1a for Acute Stroke
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
The scales and tales of myelination: using zebrafish and mouse to study myelinating glia.
Santhera's Phase III program with Catena®/Raxone® in Duchenne muscular dystrophy on track to deliver pivotal data early in 2Q 2014
The immunopathology of multiple sclerosis: an overview.
Regulation of prefrontal cortex myelination by the microbiota.
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion

Pages